Cogent Biosciences (COGT) Operating Expenses (2017 - 2026)
Cogent Biosciences (COGT) posted quarterly Operating Expenses of $103.6 million for Q1 2026, up 38.27% year-over-year from $74.9 million in Q1 2025, and up 4.13% quarter-over-quarter from $99.5 million in Q4 2025.
Cogent Biosciences (COGT) Operating Expenses (2017 - 2026) Analysis & Trends
Cogent Biosciences (COGT) has reported Operating Expenses for 10 consecutive years, with $103.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Expenses rose 38.27% year-over-year to $103.6 million; the TTM figure through Mar 2026 stood at $362.0 million (up 25.5% YoY), while the FY2025 annual figure was $333.4 million, up 20.81% from the prior year.
- Operating Expenses advanced to $103.6 million in Q1 2026 per COGT's latest filing, from $99.5 million in the prior quarter.
- Across five years, Operating Expenses topped out at $103.6 million in Q1 2026 and bottomed at $31.4 million in Q1 2022.
- Historically, Operating Expenses has averaged $62.9 million across 5 years, with a median of $62.4 million in 2024.
- Annual changes were most pronounced in 2022 — Operating Expenses jumped 145.45% — and 2025, when it grew 10.53%.
- Cogent Biosciences' Operating Expenses stood at $43.7 million in 2022, then soared by 33.11% to $58.2 million in 2023, then rose by 26.63% to $73.7 million in 2024, then surged by 34.94% to $99.5 million in 2025, then climbed by 4.13% to $103.6 million in 2026.
- Business Quant data shows COGT's Operating Expenses at $103.6 million in Q1 2026, $99.5 million in Q4 2025, and $83.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Cogent Biosciences | 6.58 Bn | 6.58 Bn | - | 102.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 102.64 Mn |
| Mar 31, 2026 | 103.61 Mn |
| Dec 31, 2025 | 99.49 Mn |
| Sep 30, 2025 | 83.36 Mn |
| Jun 30, 2025 | 75.58 Mn |
| Mar 31, 2025 | 74.93 Mn |
| Dec 31, 2024 | 73.73 Mn |
| Sep 30, 2024 | 75.41 Mn |
| Jun 30, 2024 | 64.39 Mn |
| Mar 31, 2024 | 62.40 Mn |
| Dec 31, 2023 | 58.23 Mn |
| Sep 30, 2023 | 59.58 Mn |
| Jun 30, 2023 | 47.09 Mn |
| Mar 31, 2023 | 43.24 Mn |
| Dec 31, 2022 | 43.75 Mn |
| Sep 30, 2022 | 36.82 Mn |
| Jun 30, 2022 | 35.86 Mn |
| Mar 31, 2022 | 31.42 Mn |
| Dec 31, 2021 | 25.64 Mn |
| Sep 30, 2021 | 19.82 Mn |